Collegium Pharmaceutical (NASDAQ:COLL) Receives Neutral Rating from Piper Sandler

Posted by Brenda Bartman on Aug 8th, 2026

Piper Sandler reiterated their neutral rating on shares of Collegium Pharmaceutical (NASDAQ:COLL – Free Report) in a research report released on Friday,Benzinga reports. Piper Sandler currently has a $43.00 target price on the specialty pharmaceutical company’s stock, down from their prior target price of $45.00.

COLL has been the subject of several other reports. Wall Street Zen downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 25th. Needham & Company LLC lowered their price target on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating on the stock in a research report on Thursday. Truist Financial raised shares of Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th. Zacks Research lowered Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Collegium Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average price target of $52.60.

Check Out Our Latest Stock Report on COLL

Collegium Pharmaceutical Stock Up 1.2%

COLL opened at $29.47 on Friday. The company has a debt-to-equity ratio of 3.50, a quick ratio of 1.62 and a current ratio of 1.14. The company has a market cap of $955.71 million, a price-to-earnings ratio of 23.77 and a beta of 0.73. Collegium Pharmaceutical has a one year low of $28.01 and a one year high of $50.79. The business’s fifty day moving average is $34.78 and its two-hundred day moving average is $37.07.

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The business had revenue of $199.88 million during the quarter, compared to analysts’ expectations of $199.62 million. During the same quarter last year, the business posted $1.68 earnings per share. The business’s revenue for the quarter was up 6.3% on a year-over-year basis. Analysts anticipate that Collegium Pharmaceutical will post 6.76 EPS for the current fiscal year.

Institutional Trading of Collegium Pharmaceutical

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in Collegium Pharmaceutical by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock worth $104,465,000 after buying an additional 29,876 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in shares of Collegium Pharmaceutical by 65.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock worth $60,776,000 after acquiring an additional 518,721 shares during the period. Louisiana State Employees Retirement System acquired a new stake in shares of Collegium Pharmaceutical in the first quarter worth approximately $463,000. Intech Investment Management LLC grew its holdings in Collegium Pharmaceutical by 25.5% in the fourth quarter. Intech Investment Management LLC now owns 108,855 shares of the specialty pharmaceutical company’s stock valued at $5,040,000 after purchasing an additional 22,146 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new position in Collegium Pharmaceutical during the first quarter worth approximately $686,000.

More Collegium Pharmaceutical News

Here are the key news stories impacting Collegium Pharmaceutical this week:

Positive Sentiment: Second-quarter adjusted EPS was $1.92, above analyst expectations of approximately $1.72, while revenue increased 6.3% year over year to $199.9 million. Adjusted EBITDA rose 8% to $113.8 million and operating cash flow was $71.3 million. Collegium Pharmaceutical Q2 Earnings Beat
Positive Sentiment: The ADHD portfolio showed momentum: JORNAY PM revenue climbed 41% to $46.1 million, and the completed AZSTARYS acquisition contributed $12.9 million in partial-quarter revenue. Collegium raised its full-year AZSTARYS revenue outlook to $65 million-$75 million from $60 million-$70 million, potentially supporting longer-term growth. Collegium Q2 2026 Results
Neutral Sentiment: Piper Sandler reaffirmed its “neutral” rating but lowered its price target to $43 from $45. Needham retained a “buy” rating while cutting its target to $46 from $56, reflecting continued upside but greater near-term caution. Analyst Price Target Updates
Negative Sentiment: Collegium reduced full-year product-revenue guidance to $825 million-$855 million from $865 million-$895 million and lowered adjusted EBITDA guidance to $445 million-$470 million from $475 million-$500 million. The company cited lower pricing and weaker-than-expected authorized-generic Nucynta revenue.
Negative Sentiment: The pain portfolio declined 9% year over year to $140.9 million; Nucynta revenue fell 24% and Xtampza ER revenue dropped 14%. GAAP results also shifted to a $15.1 million net loss from $12.0 million of net income, while operating expenses increased 45%, adding pressure to profitability. Collegium Sales and Guidance Report

About Collegium Pharmaceutical

(Get Free Report)

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.